Navigation Links
PharmAthene Appoints Jeffrey W. Runge, M.D. to the Company's Board of Directors
Date:12/21/2009

including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.

SOURCE PharmAthene, Inc.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
2. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
3. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
4. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
5. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
6. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
7. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
8. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
9. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
10. PharmAthene Reports First Quarter 2009 Financial and Operational Results
11. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 US-Australian drug discovery company, Novogen ... CanTx, Inc., and Yale University, on March 27 released ... was presented as an oral presentation by Professor ... to the 62 nd Annual Scientific Meeting of ... Francisco, CA. In both in ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 /PRNewswire/ ... two studies in which Caris Molecular Intelligence®, the ... molecular similarities and differences between several rare and ... treatment strategies that have the potential to improve ... Poster Session B at the Society of Gynecologic ...
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) ... and high prices in 2008. However, the situation has ... on gaining momentum now. , To date, the world ... 100,000 thousand tonnes. No considerable growth was registered in ... rocketed during 2012-2013, registering 11% growth as against the ...
Breaking Biology Technology:Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3
... DOYLESTOWN, Pa., June 12 The Quigley Corporation, (Nasdaq: ... , today announced the resignation of Guy J. ... The resignation is effective immediately, following a proxy contest which ... dissident shareholder Ted Karkus and his proposed slate of directors. ...
... ... Non-Invasive DNA Collection On-Site at Komen Western New York Race for the Cure® , ... Ottawa, ON (PRWEB) June 12, 2009 -- DNA ... partnered with the Roswell Park Cancer Institute (RPCI) to collect DNA saliva samples on-site ...
... crystalline form of carbon, whose extraordinary electron mobility and ... and photonics. But there,s a catch: graphene has no ... uses in electronics," says Feng Wang of the U.S. ... is a member of the Materials Sciences Division. "For ...
Cached Biology Technology:Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago 2Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago 3DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 3Bilayer graphene gets a bandgap 2Bilayer graphene gets a bandgap 3Bilayer graphene gets a bandgap 4
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Pa., Jan. 31, 2013   Shareholder rights attorneys ... BioClinica, Inc. (NASDAQ: BIOC ) by JLL ... biotechnology, and medical device companies. (Logo: ... 2013, BioClinica announced that it had entered into a ...
... medical technology leaders,Simon Fraser University and Fraser Health ... research and technology innovation with the launch of ... Leadership Chair in Multimodal Technology for Healthcare Innovation., ... Family Development, today announced the appointment of Simon ...
... especially in the coming years, when the International Energy ... renewable power. But what does science need to do ... Recently, three researchers discussed this with fellow scientist Harry ... Research Center on Light-Material Interactions in Solar Energy Conversion, ...
Cached Biology News:Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders' Best Interests 2Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders' Best Interests 3Leadership Chair to champion tech devices for brain trauma, disease 2Solar power: Is it time for the big push? 2
... Antibody Binding: High, 400 ng IgG/cm ... , Binding Interaction: Hydrophobic/Ionic , Performance Certified: ... Flat , Maximum Well Volume: 360 µl ... ,Features, Special optically clear polystyrene ...
... of Caspase/DIABLO Liquid. In 100 mM ... CYCLES. Amino acid residues 56 - 239 of ... sequence was expressed in and purified from ... with cytochrome c during apoptosis and ...
... JASCO offers a dedicated system for ... modular LC-1500 series of HPLC instrumentation. JASCO ... enhance the capability of the system: ,- ... chromatography and extraction procedures using carbon dioxide ...
... was originally formulated to support the growth ... gum moth,Antherea eucalypti. The medium is a ... resembleAnthereahemolymph. The cell lines established by Grace ... lines developed. The basal medium, when properly ...
Biology Products: